Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11604883 | 0.92 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL28623121 | 0.90 | AOC3 (0.58) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL2032779 | 0.87 | ADRA1A (0.61) | AOC3L3MBTL1KDM4ETSHRMAPK1 | |
| SCHEMBL27650625 | 0.87 | ADRA1A (0.61) | AOC3L3MBTL1KDM4ETSHRMAPK1 | |
| SCHEMBL835948 | 0.87 | ADRA1A (0.61) | AOC3L3MBTL1KDM4ETSHRMAPK1 | |
| SCHEMBL11607083 | 0.86 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL43735 | 0.86 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL343726 | 0.86 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL43520 | 0.86 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL11697885 | 0.85 | ADRA1A (0.59) | AOC3L3MBTL1KDM4EMAPK1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309730-B2 | Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| CN-1543455-B | 3-phenoxy-4-pyridazinol derivatives and herbicidal compositions containing the same | SANKYO AGRO CO LTD | 2012-07-11 | — | — | CN | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20110263494-A1 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | disclosed |
| US-6887820-B1 | For producing optically active secondary alcohols, producing optically active compounds useful for various utilities such as intermediates for synthesizing pharmaceutical agents, liquid crystal materials and agents for optical resolution | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-05-03 | — | — | US | disclosed |
| US-6184381-B1 | USEFUL AS INTERMEDIATES FOR SYNTHESIZING PHARMACEUTICAL CHEMICALS, LIQUID CRYSTAL MATERIALS AND AGENTS FOR OPTICAL RESOLUTION, REDUCTION, KETONES TO ALCOHOL, IMINES TO AMINES | JAPAN SCIENCE & TECHNOLOGY CORP. (JP) | 2001-02-06 | — | — | US | disclosed |
| WO-1998057910-A2 | CYCLOOXYGENASE-I SELECTIVE INHIBITORS AND THE USE THEREOF AS ANALGESIC, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1998-12-23 | — | — | WO | disclosed |
| US-4094994-A | ANTICANCER AGENTS, TUMOR INHIBITION, HORMONE-DEPENDENT CARCINOMAS | KLINGE PHARMA GMBH (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263494-A1 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF | NFKBIA, RELA, NR3C1 | AOC3 3161/4885L3MBTL1 4671/4885CHRM2 2180/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | AOC3 2749/4885L3MBTL1 2460/4885CHRM2 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.